← Research library

Myelopeptides and their therapeutic use — US6469137B1

Patent disclosure · 2002

What the patent describes
Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.
Reported evidence
MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.

MP-4 leukemia-cell differentiation · Approximately 60% mature monocyte/macrophage forms reported among the examined cells · In-vitro morphology endpoint, not a leukemia remission rate

Reported patent results

Reported findings

MP-4 induced a differentiation-like phenotype in leukemia cells; the individual myelopeptides did not act uniformly across the assays.

Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.

Population or model Myelopeptide experiments in leukemia-cell differentiation and short-term cell viability; no human treatment cohort.

Results · MP-4 differentiation section and limited cell-viability observations; no pathogen-production methods included.
MeasureResultComparison, timing and statistics
MP-4 leukemia-cell differentiationApproximately 60% mature monocyte/macrophage forms reported among the examined cellsIn-vitro morphology endpoint, not a leukemia remission rate
Short-term viabilityNo visible damage reported for the tested MP-3–MP-6 cell-culture conditionsA limited cell assay, not clinical or long-term safety · 24-hour observation

Cell differentiation, assay response and lack of visible short-term damage do not establish efficacy or safety of Myelopid in patients. Individual peptides and mixtures must remain distinct.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Molecule. Defined myelopeptide-related sequences and their proposed immune applications; the patent does not validate every Myelopid preparation.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US6469137B1 ↗ · 2002-10-22
Earliest priority / filing
1997-01-07 / 1998-01-07
Original applicant / assignee
Primamedic Ltd
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
10805577 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Myelopeptides and their therapeutic use

Inventors: Rem V. Petrov; Augusta A. Mikhailova; Larissa A. Fonina; Sergei A. Guriyanov.

US6469137B1 · US20030083236A1 · EP0960122A1 · JP2001508435A · AU728539B2 · CA2274731A1 · GB9700154D0 · NZ336243A · RU2198178C2 · WO1998030581A1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Patent efficacy proposals are not clinical evidence.
  • Commercial product names require formulation-specific confirmation.

Source details

Selected original-source text checked; full methodological review pending.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Myelopeptides and their therapeutic use — US6469137B1 Primary source linked above

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards